VRCAVerrica Pharmaceuticals Inc.Not started yet
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
Common Warts · Common Warts (Verruca Vulgaris) · Human Papilloma Virus (HPV) · Warts
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 30 (planned)
- Started
- Oct 2026
- Main results expected
- Apr 2027
- Fully finished
- Apr 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of subjects exhibiting systemic exposure to YCANTH (VP-102)
Measured over: Predose, 2 hours, 6 hours, and 24 hours after study drug application
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07881952 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC